The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Correlation of absolute and relative eosinophil counts with immune-related adverse events in melanoma patients treated with ipilimumab.
Katja Schindler
Honoraria - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
Other Remuneration - Bristol-Myers Squibb
Kaan Harmankaya
No relevant relationships to disclose
Deborah Kuk
No relevant relationships to disclose
Joanna Mangana
No relevant relationships to disclose
Olivier Michielin
Honoraria - Bristol-Myers Squibb
Christoph Hoeller
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Reinhard Dummer
Consultant or Advisory Role - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Cephalon; GlaxoSmithKline; MSD; Novartis; Roche
Honoraria - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; GlaxoSmithKline; MSD; Novartis; Roche
Research Funding - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; GlaxoSmithKline; MSD; Novartis; Roche
Hubert Pehamberger
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
Other Remuneration - Bristol-Myers Squibb
Jedd D. Wolchok
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
Michael Andrew Postow
Consultant or Advisory Role - Bristol-Myers Squibb (U)
Research Funding - Bristol-Myers Squibb